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ABSTRACT
The expansion of chondrocytes in automated bioreactors for clinical use requires that a relevant number
of cells be generated, starting from variable initial seeding densities in one passage and using autolo-
gous serum. We investigated whether the growth factor combination transforming growth factor beta
1/fibroblast growth factor 2/platelet-derived growth factor BB (TFP), recently shown to enhance the pro-
liferation capacity of human articular chondrocytes (HACs), allows the efficiency of chondrocyte use to be
increased at different seeding densities and percentages of human serum (HS). HACs were seeded at 1,000,
5,000, and 10,000 cells/cm2 inmedium containing 10% fetal bovine serum or 10,000 cells/cm2 with 1%, 5%,
or 10%HS. The chondrogenic capacity of post-expanded HACs was then assessed in pellet cultures. Ex-
pansion with TFP allowed a sufficient number of HACs to be obtained in one passage even at the lowest
seeding density and HS percentage and variability in cartilage-forming capacity of HACs expanded under
the different conditions to be reduced. Instead, larger variations and insufficient yields were found in the
absence of TFP. By allowing large numbers of cells to be obtained, starting from a wide range of initial
seeding densities and HS percentages, the use of TFP may represent a viable solution for the efficient
expansion of HACs and addresses constraints of automated clinical bioreactor systems.
INTRODUCTION
ARTICULAR CARTILAGE has a limited capacity for self-repair, and if left untreated, cartilage defects can lead to
the early onset of osteoarthritic degenerative changes. Prom-
ising approaches to induce cartilage repair are based on the
implantation of autologous chondrocytes directly after ex-
pansion1 or after loading and culture on specific scaffolds.2–5
The manufacture of cell-based products for cartilage repair
typically requires shipment of a small cartilage biopsy to
Good Manufacturing Practice (GMP) facilities, where chon-
drocytes are isolated, expanded in culture flasks, and shipped
back to the healthcare center. These procedures are, however,
associatedwith complicated logistics and, because of the pre-
dominance of manual handling steps, to limited standardi-
zation and ultimately high costs.
The use of bioreactors within the hospital or healthcare
center for automated culture of autologous cells would elim-
inate logistical issues of transferring specimens between
locations, reduce the need for large and expensive GMP fa-
cilities, and minimize operator handling, with the final possi-
ble result of simplifying, reducing the cost, and increasing
the standardization of chondrocyte-based cartilage repair
techniques. One example of this, Autologous Clinical Tissue
Engineering System (ACTES), under development by Mil-
leniumBiologix (www.millenium-biologix.com), is a closed
bioreactor system aimed at fully automating the processes of
cartilage biopsy digestion, chondrocyte expansion, rinsing,
1Institute for Surgical Research and Hospital Management, University Hospital Basel, Basel, Switzerland.
2Millenium Biologix AG, Zu¨rich-Schlieren, Switzerland.
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and concentration in a defined medium volume.6 However,
in a bioreactor system like ACTES, cells have to be ex-
panded in only one passage, and because of the fixed area of
the culture surface and the variable size of cartilage biopsies,
the initial cell seeding densities may be highly variable be-
tween production batches. Moreover, the system should use
human autologous serum at low percentages, to avoid use of
animal-derived factors and to reduce the dependence of the
culture on a non-standardized factor such as autologous
serum. With these constraints, the bioreactor system should
yield at least 12 million chondrocytes, because typical au-
tologous chondrocyte implantation is indicated to treat car-
tilage defects up to 12 cm2 in size by injection of at least 1
million cells per cm2 defect.7
With the ultimate goal of defining suitable operating con-
ditions for systems likeACTES, in thepresent studyweaimed
at determining whether a clinically relevant number (12
million) of human articular chondrocytes (HACs) can be
generated in 1 passage starting from variable initial seeding
densities and using low percentages of human serum, as-
suming a culture surface area of 250 cm2, currently in use in
the ACTES system. Specific growth factors, namely trans-
forming growth factor beta 1 (TGFb-1), fibroblast growth
factor 2 (FGF-2), and platelet-derived growth factor type BB
(PDGF-BB) (TFP), previously shown to increase the pro-
liferation efficiency of HACs,8,9 were tested to reduce the
variability in the yield of HACs under the different condi-
tions. Because the quality of HAC expansion is related not
only to the number but also to the cartilag-forming capacity
of the expanded cells, HACs grown under the different ex-
perimental conditions were assessed in a micromass pellet
culture model typically used to investigate the chondrogenic
capacity of various cells types.10,11
MATERIALS AND METHODS
Human serum
Pools of human serum (HS) were purchased by Blut-
spendezentrum SRK Bern AG, and serum from 3 healthy
donors was isolated from Blutzentrum, University Hospi-
tal Basel, Basel, Switzerland. The sera were aliquoted and
stored at 208C until ready for use. Heat inactivation of the
sera was not performed.
Cartilage sample collection and cell isolation
Full-thickness human articular cartilage biopsies were
obtained postmortem (within 24 h after death) from the lat-
eral condyle of knee joints of 5 individuals (mean age 42.7,
range 27–61) with no history of joint disease, after informed
consent by relatives and in accordance with the local ethics
committee ofUniversityHospital Basel, Switzerland. The bi-
opsies used, although they were not derived from a traumatic
joint, would be relevant for our target clinical application
(e.g., treatment of cartilage injuries), considering the es-
tablished similarity between chondrocytes surrounding a
cartilage defect or from normal cartilage.12 Cartilage tissues
were minced and then digested with 0.15% type II collage-
nase (10mL solution/g tissue, 300U/mg, Worthington Bio-
chemical Corporation, Lakewood, NJ) for 22 h, and the
isolated chondrocytes were then seeded and expanded as
described below.
Cell expansion
Cell seeding at different densities. Freshly isolated HACs
were seeded at 1,000, 5,000 or 10,000 cells/cm2 with
Dulbecco’smodified Eaglemedium (DMEM) containing 4.5
mg/mL D-glucose, 0.1mM nonessential amino acids, 1mM
sodium pyruvate, 100mM N-2-hydroxyethylpiperazine-N0-
2-ethanesulfonic acid buffer, 100U/mL penicillin, 100 mg/
mL streptomycin, and 0.29mg/mL L-glutamate (basic me-
dium)supplementedwith10%fetalbovineserum(FBS)with-
out (CTR) or with the addition of growth factors (1 ng/mL
TGFb1, 5 ng/mL FGF-2, and 10 ng/mL PDGF-BB) (TFP)13
and expanded in monolayer for 1 passage in a humidified
378C/5% carbon dioxide (CO2) incubator. Medium was
changed twice a week.
The densities 1,000 cells/cm2 and 5,000 cells/cm2 were
used considering the size of a cartilage biopsy usually pro-
vided from patients undergoing autologous chondrocyte
implantation (100–500mg),7 a normal yield after tissue di-
gestion (2.6106 cells/g)14 and the available cell expansion
surface in ACTES system (250 cm2),6 whereas 10,000 cells/
cm2 was considered to be a standard cell-seeding density.13,15
When HACs reached confluence, they were rinsed with
phosphate buffered saline, detached by treatment with 0.3%
type II collagenase, followed by 0.05% trypsin/0.53mM
ethylenediamine tetraacetic acid (EDTA), counted, and used
to generate pellets as described below.
Use of different percentages of human serum. Freshly
isolated HACs were seeded at 10,000 cells/cm2 with basic
medium supplemented with 1%, 5%, or 10% HS without or
with supplementation of the growth factor combination TFP
and expanded in monolayer for 1 passage in a humidified
378C/5% CO2 incubator. Cells from 1 additional individual
(male, 51 years old) were also cultured with 1%, 5%, or 10%
serum obtained from 3 different donors.
Three-dimensional pellet cultures
To assess the quality of the expanded chondrocytes, HACs
were induced to re-differentiate in pellet cultures as previ-
ously described.8 Briefly, HAC were suspended in basic
medium supplemented with ITSþ 1 (Sigma Chemical, St.
Louis, MO; i.e., 10mg/mL insulin, 5.5mg/mL transferrin,
5 ng/mL selenium, 0.5mg/mL bovine serum albumin,
4.7mg/mL linoleic acid), 0.1mM ascorbic acid 2-phosphate,
1.25mg/mL human serum albumin, 107 M dexamethasone
and 10 ng/mL TGF-b1 (chondrogenic medium). Aliquots of
5105 cells/0.5mL were centrifuged at 250 g for 5min in
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1.5-mL polypropylene conical tubes (Sarstedt, Nu¨mbrecht,
Germany) to form pellets, which were placed onto an orbital
shaker (Bioblock Scientific, Frenkendor, Switzerland) at
30 rpm. Pellets were cultured for 2 weeks, with medium
changes twice per week, and subsequently processed for
histological, immunohistochemical, and biochemical analy-
sis as described below. Each analysis was performed inde-
pendently on at least 2 entire pellets for each primary culture
and expansion condition.
Analytical methods
Proliferation rate. Proliferation rate was calculated as the
ratio of log2(N/N0) to T, where N0 and N are the numbers
of cells respectively at the beginning and end of the expan-
sion phase, log2(N/N0) is the number of cell doublings, and
T is the time required for the expansion.
Histological and Immunohistochemical analysis. Pellets
were fixed in 4% formalin for 24 h at 48C, embedded in
paraffin, cross-sectioned (5 mm thick), and stained with Saf-
ranin O for sulfated glycosaminoglycans (GAGs). Sections
were also processed for immunohistochemistry to visualize
collagen type II (II-II6B3, Hybridoma Bank, University of
Iowa, Iowa City, IA), as previously described.16
Biochemical analysis. Pellets were digested with protease
K (0.5mL of 1mg/mL protease K in 50mM Tris with 1mM
EDTA, 1mM iodoacetamide, and 10 mg/mL pepstatin-A) for
15 h at 568C, as previously described.17 GAG amounts were
measured spectrophotometrically using dimethylmethylene
blue,18 with chondroitin sulfate as a standard, and normal-
ized to the deoxyribonucleic acid (DNA) amounts, measured
spectrofluorometrically using the CYQuant cell prolifera-
tion assay Kit (Molecular Probes, Eugene, OR) and with calf
thymus DNA as a standard. GAG contents are reported as mg
GAG/mg DNA.
Statistical analysis. All values are presented as means
standard deviation of measurements from 4 to 5 independent
experiments (with cells from the 4–5 different individuals).
The coefficient of variation (standard deviation as a per-
centage of the mean), was used to assess the variability of
a certain parameter under different culture conditions. Dif-
ferences between experimental groups were assessed using
Mann-Whitney tests and considered statistically significant
at p< 0.05.
RESULTS
Cell seeding at different densities
Cell proliferation. This set of experiments was performed
using medium containing 10% FBS.
In CTR medium, HACs seeded at 10,000 and 5,000 cells/
cm2 proliferated at comparable rates. Cells reached conflu-
ence within 15 to 19 days of culture and underwent a similar
number of doublings (2.2 and 2.9, respectively) (Table 1).
Instead, HACs seeded at 1,000 cells/cm2 required more than
3 weeks to reach confluence, and during this time they un-
derwent 2.2-fold more doublings than cells seeded at the
highest density (Table 1). In general, a decrease in cell den-
sity paralleled enhanced HAC expansion; the total cell dou-
blings were 4.8, 2.9, and 2.2 for cells seeded at the densities
of 1,000, 5,000 and 10,000 cells/cm2, respectively (Table 1).
In medium containing growth factors (TFP medium), at
any seeding density, chondrocytes proliferated at a remark-
ably and significantly higher rate (up to 3.5-fold), reached
confluence in a shorter time (up to 2.0-fold) and underwent
more doublings (up to 1.9-fold) than HACs cultured in CTR
medium (Table 1). As observed for cells cultured in CTR
medium, doublings of HACs expanded with TFP increased
by decreasing seeding density (7.6, 5.4, and 3.9 for the
seeding densities of 1,000, 5,000 and 10,000 cells/cm2, re-
spectively). Expansion with TFP resulted in reduced vari-
ability in the proliferation rates of HACs seeded at the
different seeding densities, with the coefficient of variation
decreasing from 27.5 to 14.6.
We then used the doublings measured under the different
conditions to estimate the number of HACs that would be
obtained if chondrocytes were seeded in the culture surface
of the ACTES system (equal to 250 cm2). The required num-
ber for clinical-scale expansion (12 million cells) would not
TABLE 1. EXPANSION OF HUMAN ARTICULAR CHONDROCYTES (HAC) IN RELATION TO SEEDING DENSITY
1000 cells/cm2 5000 cells/cm2 10000 cells/cm2
Doublings
Expansion
time (days)
Proliferation
rate Doublings
Expansion
time (days)
Proliferation
rate Doublings
Expansion
time (days)
Proliferation
rate
CTR 4.8 0.4* 24.3 3.1* 0.20 0.04* 2.9 0.8 18.7 2.1 0.17 0.05 2.2 0.6 15.0 2.6 0.15 0.04
TFP 7.6 0.8*8 12.0 1.6*8 0.64 0.05*8 5.4 0.7*8 10.6 1.8*8 0.51 0.068 3.9 0.68 7.6 0.58 0.52 0.078
TFP/CTR 1.6 0.5 3.2 1.9 0.6 3.0 1.8 0.5 3.5
HAC were seeded in monolayer at different densities in medium containing 10% fetal bovine serum and cultured without growth factors (CTR) or with
transforming growth factor beta 1, fibroblast growth factor 2, and platelet-derived growth factor type BB (TFP) for 1 passage. For the calculation of the
parameter see the Materials and Methods section. Results are means standard deviations of values from 4 to 5 independent donor cells populations.
*p< 0.05 from 10,000 cells/cm2; 8p< 0.05 from CTR.
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be reached for any of the seeding densities in CTR medium,
whereas expansion with TFP would yield more than 40
millions of cells for each seeding density condition (Fig. 1A).
Chondrogenic capacity. Because not only the number of
cells obtained after expansion, but also their quality, is a
clinically relevant issue, we evaluated the chondrogenic ca-
pacity of cells expanded in the different conditions in a pellet
culture model. HACs seeded at 10,000 and 5,000 cells/cm2
produced tissues that stained similarly with Safranin O,
whereas cells seeded at 1,000 cells/cm2 generated pellets
with a lower staining intensity (Fig. 2A). Biochemical anal-
ysis of the pellets confirm this trend, although because of the
large donor-to-donor variability, no statistically significant
difference in the GAG contents of the generated tissues
could be measured between the experimental conditions.
Expansion with TFP reduced the variability in the GAG con-
tents of pellets produced by cells seeded at different densities
histologically and biochemically, with the coefficient of var-
iation for the GAG/DNA contents decreasing from 37.5% to
24.5% (Fig. 2B).
Cell expansion using different percentages of HS
Cell proliferation. This set of experiments was performed
using an initial seeding density of 10,000 cells/cm2.
In CTR medium, HACs cultured with 10% and 5% HS
proliferated at comparable rates. Cells reached confluence
within 9.5 to 10.5 days of culture and underwent a similar
number of doublings (2.5 and 2.1, respectively) (Table 2).
However, cells expanded with 1% HS required more time to
reach confluence (1.4-fold) and underwent fewer doublings
(2.1-fold) than chondrocytes cultured with 10% HS (Table
2). Chondrocytes displayed a higher proliferation rate overall
(1.9-fold) when cultured with 10% HS than with 10% FBS
(see Table 1 and 2).
In TFP medium, HACs cultured at any HS percentage
proliferated at a higher rate than those cultured in CTR me-
dium, although because of large donor-to-donor variability,
statistical significance was established only for the lowest
serum concentration. At 1% HS, TFP-expanded chondro-
cytes reached confluence in a shorter time (1.6-fold) and un-
derwent more doublings (2.3-fold) than CTR-expanded cells
(Table 2). Expansion with TFP resulted in less variability in
the proliferation rates of HACs cultured with the different
FIG. 1. Predicted number of human articular chondrocytes
(HACs) that would be obtained after expansion in a culture sur-
face comparable to that of Autologous Clinical Tissue Engineer-
ing System (250 cm2) under different conditions of initial seeding
densities (A) or percentage of human serum (HS) (B). Results are
means  standard deviations of values from 4 to 5 independent
donor cells. Fractions over each bar represent the ratio of cultures
that reached a minimum of 12 million to total cultures analyzed.
FIG. 2. Glycosaminoglycan (GAG) accumulation in pellets gen-
erated by human articular chondrocytes (HACs) after expansion
under different initial seeding density conditions. (A) Safranin O
staining of representative pellets generated by HACs seeded at
1,000 (I and IV), 5,000 (II and V), or 10,000 (III and VI) cells/cm2
and expanded in CTR (I, II, and III) or TFP (IV, V, and VI) me-
dium. Bar¼ 100 mm. (B) GAG content normalized to the amount of
deoxyribonucleic acid (DNA) (GAG/DNA) in the pellets generated
by HACs expanded under the different conditions. Results are
means standard deviations of values from 4 to 5 independent
donor cell populations. Coefficients of variation (CVs) over each
bar are the standard deviations (as % of the mean) of the GAG
contents measured at the different cell-seeding densities. Color
images available online at www.liebertpub.com/ten.
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concentrations of HS, with the coefficient of variation de-
creasing from 45.3 to 22.2.
In CTR medium, cells cultured with 1% HS would not
yield the required number of cells (12 million) if cultured
under the same conditions in the culture surface of the
ACTES system (250 cm2), whereas in TFP medium, more
then 20 million chondrocytes would be generated for each
HS percentage (Fig. 1B).
Chondrogenic capacity. HACs expanded in CTRmedium
with 10% and 5%HS produced tissues similarly stained with
Safranin O, whereas cells expanded with 1% HS generated
pellets with a lower staining intensity (Fig. 3A). Biochem-
ical analysis of the pellets confirmed this trend, but because
of the large donor-to-donor variability, no statistically sig-
nificant difference in the GAG contents of the generated
tissues could be established between the experimental con-
ditions. Expansion with TFP reduced variability in the GAG
contents of pellets produced by cells cultured with different
HS percentages, with coefficient of variation decreasing
from 11.6% to 4.4% (Fig. 3B). Tissues that contained large
amounts of GAG generally contained higher amounts of
collagen type II protein, as assessed using immunohisto-
chemical staining (Fig. 3C).
To determinewhetherHS fromdifferent donors could pro-
mote cell proliferation and re-differentiation capacity differ-
ently, chondrocytes from 1 additional cartilage biopsy were
expanded in TFP medium with serum obtained from 3 dif-
ferent donors and then cultured in pellets. For each HS per-
centage condition used (1%, 5%, and 10%), cells proliferated
at similar rates (coefficient of variation< 6.0). However, a
greater percentage of HS used during the expansion resulted
in enhanced variability in the GAG contents of pellets
generated by cells expanded with serum from different do-
nors, with the coefficients of variation of 4.7, 19.5, and 46.1
for 1%, 5%, and 10% HS, respectively (Fig. 4).
DISCUSSION
With the final goal of validating culture conditions for
clinical-scale expansion of HACs, we investigated the pro-
liferation capacity of HACs cultured starting from a wide
range of initial seeding densities (1,000, 5,000, and 10,000
cells/cm2) and HS percentages (1%, 5%, and 10%) in me-
dium not supplemented and supplemented with growth
factors. We found that expansion with CTRmedium was not
reproducible and did not yield a clinically relevant number
of chondrocytes (12 millions) at each seeding density
condition and at the lowest percentage of HS. Using TFP
medium, instead, proliferation capacity was strongly en-
hanced such that 22 to 55 million chondrocytes could be
generated in the different experimental conditions tested.
Moreover, medium supplementation with TFP reduced var-
iability in proliferation and cartilage-forming capacity of
cells expanded under the different experimental conditions.
In clinical practice, the dimension of a cartilage biopsy and
therefore the number of chondrocytes available for ex vivo
expansion will vary from donor to donor. Therefore, having
the constraint of a fixed surface area, have initially evaluated
the effect of seeding density on HAC proliferation capacity.
To the best of our knowledge, this is the first study evaluat-
ing the growth capacity of articular chondrocytes of human
origin at different initial seeding densities. Similar investi-
gations have been performed using chondrocytes from non-
articular sites19,20 or of animal origin.21 Our results indicate
that HACs seeded at decreasing densities proliferated inCTR
medium with greater rates, such that a maximum number of
population doublings (4.8) was measured for HACs seeded
at 1,000 cells/cm2. Mandl et al. observed a similar relation-
ship between initial seeding density and proliferation capac-
ity with human auricular chondrocytes.20 The authors
reported that, using a density of 3,500 or 7,500 cells/cm2, a
20-fold increase in cell number was reached between pas-
sage 2 and 3 for most donors. We have demonstrated that
human articular chondrocytes seeded at 1,000 cells/cm2
undergo almost 8 doublings (corresponding to more than a
250-fold increase in cell number) in less than 2 weeks in just
1 passage while maintaining their differentiation capacity,
but only in the presence of TFP. Thus, the use of TFP during
HAC expansion allows a clinically relevant number of cells
to be obtained also if initially seeded at low densities (and
therefore starting from a cartilage biopsy of small size), re-
duces the time required for cell expansion, and reduces the
TABLE 2. EXPANSION OF HUMAN ARTICULAR CHONDROCYTES (HACs) IN RELATION TO HUMAN SERUM (HS) PERCENTAGE
1% HS 5% HS 10% HS
Doublings
Expansion
time (days)
Proliferation
rate Doublings
Expansion
time (days)
Proliferation
rate Doublings
Expansion
time (days)
Proliferation
rate
CTR 1.2 0.5* 13.5 2.6* 0.12 0.1* 2.1 0.9 10.5 3.0 0.23 0.2 2.5 0.6 9.5 2.1 0.29 0.1
TFP 2.7 1.28 8.5 1.38 0.34 0.28 3.5 1.1 8.5 1.3 0.42 0.2 3.9 0.9 8.2 1.5 0.49 0.16
TFP/CTR 2.3 0.6 2.8 1.7 0.8 1.8 1.6 0.9 1.7
HACs were seeded in monolayer at 10,000 cells/cm2 and cultured with different HS concentrations in medium without growth factors (CTR) or with
transforming growth factor beta 1, fibroblast growth factor 2, and platelet-derived growth factor type BB (TFP) for 1 passage. For the calculation of the
parameter, see the Materials and Methods section. Results are means standard deviations of values from 4 independent donor cell populations.
*p< 0.05 from 10% HS; 8p< 0.05 from CTR.
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variability in proliferation rates of cells initially seeded at
different densities. TFP-expanded chondrocytes generated
pellets with high GAG contents even if they underwent a
much larger number of doublings than cells expanded
without growth factors. With the prospective of a clinical
application, contact of human cells with FBS must be min-
imized, because proteins from ruminant materials have been
implicated in prion transmission,22,23 and European legis-
lation does not recommend their use. In the second part of
our study, we therefore evaluated the effect of using HS on
HAC proliferation capacity. Our observation that 10% of a
pool of HS supported higher proliferation of chondrocytes
than 10% FBS is in agreement with previous results obtained
using autologous HS24–26 and may be due to the higher
concentration of epidermal-derived growth factor and PDGF
measured in human serum.25 Using an initial cell seeding
density of 10,000 cells/cm2, we then showed that HAC ex-
pansion with TFP, but not with CTR medium, yielded more
than 20 million cells for any HS percentage. Because the
proliferation rate of HACs was higher using lower cell-
seeding densities (Table 1), it is likely that TFP will allow
the required cell numbers to be obtained for any HS per-
centage even at the lowest seeding densities, although this
remains to be experimentally determined. When HS from
different donors was used, similar and low coefficients of
variation in HAC proliferation rate were measured at any HS
percentage, whereas coefficients of variation in the GAG
content of resulting pelletswere dramatically greaterwithHS
percentage. This result confirms the importance of assessing
not only chondrocyte yields but also their chondrogenic ca-
pacity and also indicates the need for a reduction in the
percentage of HS used to increase reproducibility of HAC
quality. In this context, the use of TFP during HAC expan-
sion, by supporting sufficient cell yields even at low percent-
ages of HS, could also contribute to reducing the variability
FIG. 3. Glycosaminoglycan (GAG) and collagen type II accu-
mulation in pellets generated by human articular chondrocytes
(HACs) after expansion with different percentages of human serum
(HS). (A) Safranin O staining of representative pellets generated by
HACs expanded with 1% (I and IV), 5% (II and V), or 10% (III and
VI) HS in medium without growth factors (CTR) (I, II, and III) or
with transforming growth factor beta 1, fibroblast growth factor 2,
and platelet-derived growth factor type BB (TFP) (IV, V, and VI).
Bar¼ 100mm. (B) GAG content normalized to the amount of deo-
xyribonucleic acid (DNA) (GAG/DNA) in the pellets generated by
HACs expanded under the different conditions. Results aremeans
standard deviations of values from 4 independent donor cell popu-
lations. Coefficients of variation (CVs) over each bar are the
standard deviation (as % of the mean) of the GAG contents mea-
sured at the different HS percentages. (C) Collagen type II immu-
nohistochemistry staining of representative pellets generated by
HACs expanded with 1%HS in CTR (I) or TFP medium (II). Bar¼
100 mm. Color images available online at www.liebertpub.com/ten.
FIG. 4. Serum-related differences in the proliferation and gly-
cosaminoglycan (GAG) accumulation of human articular chondro-
cytes (HACs). HACs from one cartilage biopsy were expanded in
medium containing transforming growth factor beta 1, fibroblast
growth factor 2, and platelet-derived growth factor type BB (TFP)
and serum obtained from 3 different donors (A, B, and C) at in-
creasing percentages. (A) Proliferation rates of HACs. (B) GAG
contents of pellets generated by HACs. Coefficients of variation
(CVs) over each bar are the standard deviations (as % of the mean)
of the proliferation rates or GAG contents of cells expanded with
serum from the different donors.
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in the number and quality of expanded autologous chon-
drocytes.
From a regulatory standpoint, the use of recombinant
growth factors for the production of a therapeutic product
requires the appropriate level of qualification. Safety con-
cerns related to the use of TFP during HAC expansion should
have minor relevance, because extensive washing of the cell
preparation will remove these components so that they would
be virtually absent in the final graft material. However, chon-
drocyte populations generated using TFP might need to be
further analyzed for specific genetic alterations possibly re-
lated to senescence or DNA methylation before their clini-
cal use.
In conclusion, our study showed that the use of TFP
represents a viable solution for the reproducible and efficient
clinical-scale expansion of HACs. Although our findings
were based on the use of conventional tissue culture plates,
implementation of the principle would be particularly rele-
vant for automated processing systems for clinical use,
which have higher constraints than typical manual culture
in dishes. The concept of using specific growth factors in
clinical-grade bioreactors could be applied for the propa-
gation of cells from different human sources to reduce var-
iability in the number and quality of expanded cells and,
ultimately, in the clinical outcome of cell-based regenerative
techniques.
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